{"id":82519,"date":"2026-05-14T14:59:11","date_gmt":"2026-05-14T14:59:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/82519\/"},"modified":"2026-05-14T14:59:11","modified_gmt":"2026-05-14T14:59:11","slug":"novo-nordisk-combines-direct-to-patient-service-with-analyst-optimism-in-obesity-fight","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/82519\/","title":{"rendered":"Novo Nordisk Combines Direct-to-Patient Service with Analyst Optimism in Obesity Fight"},"content":{"rendered":"

Hedgeye sees up to 117% upside for Novo Nordisk as oral obesity pill prescriptions surge; home delivery via Rexall and strong clinical data support defensive strategy.<\/p>\n

The Danish drugmaker is weaving together a defensive strategy that leans on convenience as much as science. While a new home-delivery partnership with Canadian pharmacy chain Rexall aims to lock in patients for its blockbuster GLP-1 portfolio, a fresh analyst call from Hedgeye points to significant upside driven by the oral obesity pill\u2019s trajectory in the United States.<\/p>\n

Novo Nordisk\u2019s shares have already recovered nearly 20% over the past month, trading at just over \u20ac40 after touching a March low of \u20ac30.48. Yet the stock remains roughly 43% below its 52-week high and carries a trailing 30% annual loss. Analysts at Hedgeye initiated coverage on May 13 with a strikingly bullish target range of 52% to 117% upside, citing expanding demand for oral semaglutide.<\/p>\n

The hedge fund\u2019s research house forecasts 3.6 million monthly prescriptions for the oral obesity pill by late 2026. That would deliver earnings per share of $5.06 \u2014 far above the market consensus of $3.55. The valuation gap is a key hook: Novo Nordisk trades at a price-to-earnings ratio of around 13.6, while the industry average stands at 16.8.<\/p>\n

Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n

On the ground, the company is reinforcing customer loyalty through a different channel. Through Rexall Direct, patients across most of Canada can now have Ozempic, Wegovy, and Rybelsus shipped to their homes at no extra charge and at regular in-store prices. Pharmacists are available for phone consultations. The move comes as generic versions of semaglutide gain regulatory ground in Canada \u2014 a reminder that even blockbuster drugs face erosion from cheaper copycats.<\/p>\n

Clinical data presented at the European Congress on Obesity in Istanbul further burnish the brand\u2019s scientific edge. Analysis from the Phase 3 OASIS 4 and STEP UP studies showed that roughly 27% of patients on a high 7.2 mg dose of Wegovy lost at least 15% of their body weight within 24 weeks. Among early responders to the oral semaglutide pill, average weight reduction hit 21.6% over 64 weeks. With more than two million patients already taking the oral version, identifying those early signals could fine-tune treatment protocols and sustain prescription momentum.<\/p>\n

Meanwhile, Novo Nordisk quietly completed its retreat from cell therapy. On May 12, it handed over the Parkinson\u2019s program STEM-PD \u2014 which held FDA fast-track status \u2014 to the AI-driven biotech firm Cellular Intelligence. Financial terms were undisclosed; Novo Nordisk receives equity stakes and potential milestone payments. The divestiture, first flagged in late 2025, closes the chapter on the company\u2019s cell therapy unit and sharpens its focus squarely on metabolic disease.<\/p>\n

Technically, the stock has climbed roughly 18% above its 50-day moving average. Hedgeye flags a sustained daily close above $47 as a buy signal, with the next target near $54. Whether that momentum holds will likely depend on U.S. weekly prescription data for oral semaglutide, which serve as an early check on whether analyst forecasts are materializing. For now, Novo Nordisk is betting that a combination of clinical proof, direct access, and portfolio discipline can win back the ground it lost over the past year.<\/p>\n

Ad<\/p>\n

Novo Nordisk Stock: New Analysis – 14 May<\/p>\n

Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.<\/p>\n

Read our updated Novo Nordisk analysis…<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Hedgeye sees up to 117% upside for Novo Nordisk as oral obesity pill prescriptions surge; home delivery via…\n","protected":false},"author":2,"featured_media":82520,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[12273,43960,43961,43962,43963,5691,3845,272,357,30577,6917],"class_list":{"0":"post-82519","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-analyst","9":"tag-combines","10":"tag-direct-to-patient","11":"tag-fight","12":"tag-hedgeye","13":"tag-nordisk","14":"tag-novo","15":"tag-novo-nordisk","16":"tag-obesity","17":"tag-optimism","18":"tag-service"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116573527303326179","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/82519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=82519"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/82519\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/82520"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=82519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=82519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=82519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}